China's Biopharmas Should Develop Genetically Engineered Drugs, Antibody Drugs And Vaccines
This article was originally published in PharmAsia News
Executive Summary
Members of China's biopharma trade believe that during 2011-15, the sector should aim to upgrade quality assurance and develop genetically engineered drugs, antibody medicines and vaccines, which in recent years have seen a global climb in sales